Taken together, the inhibition of ADA activity and further activation of AR on platelets as well as the suppression of ADA binding to the platelets have therapeutic potential in coagulation disorders, but the effects of pharmacological intervention with ADA inhibitors in these pathological conditions require further studies. The gene discussed is ADA; the disease is blood coagulation disease.